Assessment the effect of a Persian Traditional Medicine product on cholestasis treatment

Assessment the effect of Barberrian oxymel on the clinical and laboratory symptoms of acquired chronic intra hepatic cholestasis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017082435883N1

Enrollment

Registered

2017-10-22

Start date

2017-11-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary sclerosing cholangitis, Primary biliary cirrhosis, Drug induced cholestasis. Other diseases of biliary tract, Primary biliary cirrhosis, Toxic liver disease

Interventions

Intervention without control: Barberrian oxymel includes about 10 -15 g Berberis Vulgaris that is taken hydroalcoholic extraction in oxymel 30 cc per day in 2 divided doses with Ursodeoxycholic acid t

Treatment - Drugs

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients who have chronic intra hepatic cholestasis with ages over 18 years old Which have been taken for at least 6 months Ursodeoxycholic acid (UDCA) but clinical and laboratory symptoms reduced below 50%. Exclusion criteria: Pregnancy; AIDS; Pancreatic cancer; Gastrointestinal cancer; Cholangiocarcinoma; Liver neck tumors; MELD more than 15

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bilirubin. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Measuring by the blood test in mg/L.;ALP. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Measuring by the blood test in IU/L.;AST. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Measuring by the blood test in IU/L.;ALT. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Measuring by the blood test in IU/L.;Itching. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Questionnaire.;The feeling of warmth. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Checklist.;Fatigue. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Checklist.	—

Measure

Time frame

Bilirubin. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Measuring by the blood test in mg/L.;ALP. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Measuring by the blood test in IU/L.;AST. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Measuring by the blood test in IU/L.;ALT. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Measuring by the blood test in IU/L.;Itching. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Questionnaire.;The feeling of warmth. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Checklist.;Fatigue. Timepoint: Before intervention and for 3 months after intervention. Method of measurement: Checklist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactzahra Naghibi

Faculty of Persian Traditional and Complementary Medicine, Mashhad University of Medical Science

Naghibiz931@mums.ac.ir+98 51 3882 9279

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026